Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Campochiaro, Corrado, Della-Torre, Emanuel, Cavalli, Giulio, De Luca, Giacomo, Ripa, Marco, Boffini, Nicola, Tomelleri, Alessandro, Baldissera, Elena, Rovere-Querini, Patrizia, Ruggeri, Annalisa, Monti, Giacomo, De Cobelli, Francesco, Zangrillo, Alberto, Tresoldi, Moreno, Castagna, Antonella, Dagna, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242960/
https://www.ncbi.nlm.nih.gov/pubmed/32482597
http://dx.doi.org/10.1016/j.ejim.2020.05.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242960/
https://www.ncbi.nlm.nih.gov/pubmed/32482597
http://dx.doi.org/10.1016/j.ejim.2020.05.021

Ejemplares similares